Second-Quarter Consumer Health Results Bring J&J Relief From Year-Ago Sales Plummet
Segment's Results Likely Better Than Remainder Of 2021, J&J And Analyst Say
Executive Summary
In first of what could be similar April-June earnings results from major consumer health firms, J&J reports 9.2% operational growth to $3.74bn in sales. Worldwide consumer health chief Thibaut Mongon touts segment’s results and outlook but says similar growth in second half isn’t assured.
You may also be interested in...
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.
J&J Consumer Health Sees Pandemic Accelerate Shift To Digital
J&J Consumer Health's worldwide chairman Thibaut Mongon told the recent Barclays Consumer Staples conference that COVID-19 had accelerated the shift to digital and what consumers expect from OTC brands.
J&J's CEO Gorsky Steps Aside With Duato Named His Successor
J&J's CEO Alex Gorsky is stepping down after almost 10 years in the role and will be replaced by vice chairman of the executive committee Joaquin Duato.